Chronic Kidney Disease

Kenneth Mahaffey, MD, discusses FLOW trial data showing semaglutide improves cardiovascular outcomes in patients with type 2 diabetes, regardless of CKD severity.

Findings from a recent national registry study suggest perioperative mortality after living kidney donation significantly declined in 2013-2022 compared with 1993-2002 and 2003-2012.

Findings link greater thiazide doses to increased reductions in urine calcium and fewer subsequent symptomatic kidney stone events.

A new real-world study suggests tirzepatide provides greater reductions in mortality, cardiovascular risk, and kidney events than GLP-1 receptor agonists in type 2 diabetes.

Positive topline results from the phase 3 VALIANT study show promise for pegcetacoplan in patients with C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

On August 05, 2024, less than a month prior to its presentation at ESC 24, Bayter has announced topline data from the FINEARTS-HF trial indicating finerenone met the primary endpoint.

The sNDA for furosemide seeks to expand the indication to include the treatment of edema due to fluid overload in patients with CKD, with a PDUFA date of March 6, 2025.

Spigler provides insight into the development of new patient-focused guidelines for managing hyperkalemia in CKD and the importance of providing patients with such resources.

Neuen explains the cardiovascular and kidney benefits of combining SGLT2 inhibitors and GLP-1 receptor agonists in diabetes and the future of combination therapy.

The patient-focused guidelines were developed by the American Kidney Fund and AstraZeneca to help people with CKD manage high potassium.

Findings from a meta-analysis examining 12 trials including more than 70,000 patients with diabetes support combining SGLT2 inhibitors and GLP-1 RAs.

This June 2024 month in review spotlights HCPLive’s coverage of the latest renal news and research in IgA nephropathy, differences in care, and novel associations in nephrology.

Data on outcomes stratified according to baseline use of SGLT2 inhibitors from the FLOW trial were presented at ADA 2024.

Findings highlight the potential utility of low-dose SGLT2 inhibitors for optimizing diabetes control and managing renal complications in pediatric patients with type 1 diabetes.

Results showed eGFR was linked to having ≥ 20 adult teeth in postmenopausal women, highlighting increased tooth loss among participants with CKD versus those without.

Kaitlin Mayne, MBChB, discusses an analysis of the EMPA-Kidney trial examining the effects of multimorbidity, polypharmacy, and quality of life on effects of empagliflozin.

In our nephrology month in review for May 2024, we spotlight the biggest news from the NKF and ERA meetings, including the latest updates in IgA nephropathy, C3 glomerulopathy, chronic kidney disease, and more!

Our endocrinology month in review for May 2024 highlights pipeline news in endocrinology and spotlights our coverage of the landmark FLOW trial from ERA 2024.

Our cardiology month in review spotlights the top 5 storylines that defined cardiology during May 2024, including new HCM guidelines, news from ESA 2024, and the FLOW trial.

Brendon Neuen, MBBS, PhD, joins the podcast to discuss the latest updates in nephrology, including the landmark FLOW trial.

Fadi Fakhouri, MD, PhD, discusses the 1-year results of the NOBLE trial examining use of pegcetacoplan in patients with post-transplant C3G or IC-MPGN.

A phase 2b dose-finding study suggests use of clazakizumab was associated with a reduction in hs-CRP among patients undergoing maintenance dialysis.

In the APPEAR-C3G trial, iptacopan reduced proteinuria by 35.1% in patients with C3 glomerulopathy, with Novartis planning regulatory submissions for C3G before the end of 2024.

Helen Colhoun, MD, discusses the results of a SELECT analysis she presented at the 61st European Renal Association Congress.

Semaglutide 2.4 mg reduces kidney events in SELECT participants, showing renoprotective effects in addition to cardiovascular benefits.